Evidence map›Paper›PMID 30850876›Full record

Trial reportEuropean journal of applied physiology2019

A proof-of-concept trial of HELIOX with different fractions of helium in a human study modeling upper airway obstruction.

Hubert Truebel, Sandra Wuester, Philip Boehme, Hinnerk Doll, Sven Schmiedl, Jacek Szymanski, Thorsten Langer, Thomas Ostermann, Dirk Cysarz, Petra Thuermann

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in European journal of applied physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00788788 (PoC Study of Heliox With Helium-Fractions Between 25 and 75% in Experimental Upper Airway Obstruction), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00788788 phase1 / phase2completednot on this map

PoC Study of Heliox With Helium-Fractions Between 25 and 75% in Experimental Upper Airway Obstruction

TypeinterventionalSponsorUniversity of Witten/HerdeckeRan2007Enrolled44ConditionsAirway Obstruction, DyspneaArmsHELIOX
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Hubert TruebelDepartment of Pediatrics, HELIOS Clinic Wuppertal, Wuppertal, Germany. hubert.truebel@bayer.com.
Sandra WuesterDepartment of Pediatrics, HELIOS Clinic Schwelm, Schwelm, Germany.
Philip BoehmeCardiovascular Research, Bayer Pharma AG, Apratherweg 18, 42096, Wuppertal, Germany.
Hinnerk DollSchool of Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany.
Sven SchmiedlPhilipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Germany.
Jacek SzymanskiPhilipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Germany.
Thorsten LangerDepartment of Pediatrics, HELIOS Clinic Wuppertal, Wuppertal, Germany.
Thomas OstermannSchool of Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany.
Dirk CysarzSchool of Medicine, Faculty of Health, Witten/Herdecke University, Witten, Germany.
Petra ThuermannPhilipp Klee-Institute for Clinical Pharmacology, HELIOS Clinic Wuppertal, Wuppertal, Germany.
Witten/Herdecke University · DEHelios Universitätsklinikum Wuppertal · DEBayer (Germany) · DEFH Aachen · DEUniversity of Freiburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHelium in oxygen (HELIOX) can relieve airway obstruction and lower the work of breathing because it increases the threshold at which turbulent gas flow is induced. Less turbulent and more laminar flow lowers the work of breathing. According to guidelines, the fraction of Helium in HELIOX should be maximized (e.g. to 79%). Here, we investigate whether HELIOX with less than 60% of Helium is able to relieve the sensation of dyspnea in healthy volunteers.

methods44 volunteers underwent resistive loading breathing different gases (medical air and HELIOX with a fraction of 25%, 50% or 75% helium in oxygen) in a double-blinded crossover design. Subjects rated their degree of dyspnea (primary outcome parameter) and the variability of noninvasively measured systolic blood pressure was assessed.

resultsDyspnea was significantly reduced by HELIOX-containing mixtures with a fraction of helium of 25% or more. Similarly, blood pressure variability was reduced significantly even with helium 25% during respiratory loading with the higher load, whereas with the smaller load an effect could only be obtained with the highest helium fraction of 75%.

conclusionIn this clinical trial, HELIOX with less than 60% of helium in oxygen decreased the sensation of dyspnea and blood pressure variability, a surrogate parameter for airway obstruction. Therefore, higher oxygen fractions might be applied without losing the helium-related benefits for the treatment of upper airway obstruction.

trial registrationRegistration with clinical trials (NCT00788788) and EMA (EudraCT number: 2006-005289-37).

Indexed as

AdultAirway ObstructionBlood PressureDyspneaFemaleHeliumHumansMaleOxygenOxygen Inhalation TherapyProof of Concept StudyhelioxHeliumOxygenClinical proof-of-concept studyHELIOXUpper airway obstructionWork of breathing

Identifiers

PMID30850876
OpenAlexW2921428883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.